FlowSense

FlowSense was acquired by Baxter in September 2013.

FlowSense has developed an advanced fluid monitoring system for accurate, continuous, real-time monitoring of urine output.

Product & Advantages

FlowSense’s URINFO 2000 is based on its patented optical sensing technology and unique disposable. Continuous, real-time data is collected automatically and accessible to clinicians at any time.  The product consists of two components:

  • Electronics: optical drop reader and digital display monitor with memory and event alarms
  • Disposables: proprietary urine collection and measurement unit

URINFO is available in two configurations: stand-alone system at the patients’ bedside and integrated with clinical information systems.

  • Early, ongoing assessment of fluid balance and impending risks to kidney
  • Continuous, real-time data collected automatically and accessible to clinicians at any time
  • Cost reduction resulting from early detection and treatment of kidney injury

Status

Stage: Public company (Tel Aviv Stock Exchange)
Founded: 2009
In the media: Baxter acquires FlowSense

Background

Measurement of urine output is a key indicator of a patient’s fluid balance and renal condition, particularly in the critical care setting. Acute kidney injury occurs in approximately 5% of all hospitalized patients and in 30% of critical care patients, resulting in higher costs of care and higher mortality rates.

Today, urine output is measured with mechanical urine meters, which are labor intensive, based on manual volume readings, and do not provide urine output data necessary for timely detection and treatment of kidney injury. FlowSense has developed an advanced fluid monitoring system for accurate, continuous, real-time monitoring of urine output.

Contact

Eran Feldhay, CEO Trendlines Medical
+972.72.260.7000
eran@trendlines.com

Flowsense logo